Investor Relations

Corporate Profile

Autolus is a clinical-stage, biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products to combat cancer. Utilising its advanced cell programming and manufacturing technologies, Autolus has a pipeline of products in development for the treatment of both haematological malignancies and solid tumours.

Press Releases

Nov 23, 2018
Autolus Therapeutics Submits Fiscal Year 2018 Form 20-F
LONDON , Nov. 23, 2018 /PRNewswire/ --  Autolus Therapeutics plc  (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended 2018 with the United States


More events are coming soon.